Pharmaceutical markets and insurance worldwide

The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government pla...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Άλλοι συγγραφείς: Dor, Avi, 1956-
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Bingley, U.K. : Emerald, 2010.
Σειρά:Advances in health economics and health services research ; v. 22.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04276nam a2200421Ia 4500
001 bslw07266466
003 UtOrBLW
005 20110321141157.0
006 m d
007 cr un|||||||||
008 110321s2010 enka o 000 0 eng d
020 |a 9781849507172 (electronic bk.) :  |c £82.95 ; €121.95 ; $154.95 
040 |a UtOrBLW  |c UtOrBLW  |d GrThAP 
050 4 |a HD9665.5  |b .P43 2010 
072 7 |a KCQ  |2 bicssc 
072 7 |a KDNP  |2 bicssc 
072 7 |a BUS033040  |2 bisacsh 
072 7 |a BUS000000  |2 bisacsh 
072 7 |a MED071000  |2 bisacsh 
080 |a 615 
082 0 4 |a 338.476151  |2 22 
245 0 0 |a Pharmaceutical markets and insurance worldwide  |h [electronic resource] /  |c edited by Avi Dor. 
260 |a Bingley, U.K. :  |b Emerald,  |c 2010. 
300 |a 1 online resource (xxi, 344 p.) :  |b ill. 
490 1 |a Advances in health economics and health services research,  |x 0731-2199 ;  |v v. 22 
505 0 |a Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon -- ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood. 
520 |a The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries. 
650 7 |a Business & Economics  |x Insurance  |x Health.  |2 bisacsh 
650 7 |a Business & Economics  |x General.  |2 bisacsh 
650 7 |a Medical  |x Pharmacology.  |2 bisacsh 
650 7 |a Health economics.  |2 bicssc 
650 0 |a Pharmaceutical industry. 
650 0 |a Health insurance. 
700 1 |a Dor, Avi,  |d 1956- 
776 1 |z 9781849507165 
830 0 |a Advances in health economics and health services research ;  |v v. 22. 
856 4 0 |u http://www.emeraldinsight.com/0731-2199/22  |z Full Text via HEAL-Link 
913 |1 BME2010